1. Introduction
===============

As the earliest agents used for chemotherapy, DNA alkylating nitrogen mustards have been widely utilized in oncology treatment, and many such agents are still in clinical use ([Figure 1](#molecules-19-08803-f001){ref-type="fig"}) \[[@B1-molecules-19-08803],[@B2-molecules-19-08803],[@B3-molecules-19-08803],[@B4-molecules-19-08803],[@B5-molecules-19-08803]\]. However, progress in developing new *N*-mustard agents is limited due to its drawbacks \[[@B6-molecules-19-08803]\]. Its necessarily high chemical reactivity leads to serious adverse effects \[[@B3-molecules-19-08803],[@B7-molecules-19-08803],[@B8-molecules-19-08803]\] by randomly alkylating other cellular nucleophiles. They lack specific affinity to tumor cells and induce bone marrow toxicity \[[@B6-molecules-19-08803],[@B9-molecules-19-08803]\]. To overcome those drawbacks, one of the strategies has been to synthesize bifunctional compounds by linking *N*-mustards with DNA-affine molecules, such as DNA-intercalators (e.g., acridines \[[@B6-molecules-19-08803],[@B9-molecules-19-08803],[@B10-molecules-19-08803]\], cyclopentanthraquinone \[[@B11-molecules-19-08803]\]) or DNA minor groove binders (e.g., distamycin A and related analogues \[[@B12-molecules-19-08803],[@B13-molecules-19-08803],[@B14-molecules-19-08803]\]). Previous research has demonstrated that linking with an appropriate carrier can modify the specificity of DNA alkylation and thus improve the therapeutic efficacy of *N*-mustard agents. This strategy has been widely applied in the search for new drugs \[[@B9-molecules-19-08803],[@B15-molecules-19-08803],[@B16-molecules-19-08803]\].

![Chemical structures of *N*-mustard antineoplastic drugs and derivatives.](molecules-19-08803-g001){#molecules-19-08803-f001}

Naphthalimide, a well-defined DNA-intercalator, has been extensively investigated as an antitumor agent \[[@B17-molecules-19-08803]\]. Several naphthalimide derivatives such as mitonafide, amonafide, ethonafide, elinafide, and bisnafide ([Figure 2](#molecules-19-08803-f002){ref-type="fig"}) are currently undergoing clinical trials, \[[@B17-molecules-19-08803]\]. Elinafide and bisnafide, which are bis-intercalators prepared by linking two naphthalimide groups with a polyamine linker, showed much higher cytotoxicity than the mono-intercalators mitonafide and amonafide \[[@B18-molecules-19-08803],[@B19-molecules-19-08803]\]. However, only limited research have been done in the area of linking *N*-mustard with DNA-binding naphthalimide, and they showed enhanced cytotoxicities \[[@B20-molecules-19-08803],[@B21-molecules-19-08803],[@B22-molecules-19-08803],[@B23-molecules-19-08803]\].

Herein, we designed and synthesized *N*-mustard derivatives of naphthalimides by linking the *N*-mustard moiety with naphthalimides. The conjugates acted as both alkylating agents and intercalators. Encouraged by the generally stronger cytotoxicities and high binding capacities of the bis-intercalators, we decided to synthesize both mono and bis-naphthalimide \[[@B18-molecules-19-08803]\] conjugates to compare their cytotoxic activities.

![Structures of naphthalimides and *N*-mustard analogs.](molecules-19-08803-g002){#molecules-19-08803-f002}

2. Results and Discussion
=========================

2.1. Chemistry
--------------

To attach the *N*-mustard moiety to the naphathalimide core, we synthesized compound **2** from naphthalic anhydride \[[@B24-molecules-19-08803],[@B25-molecules-19-08803]\]. Compound **2** was refluxed with an aminoalcohol in CH~3~CN to yield the key precursor compound **3**, which was converted to compound **4** by refluxing in HCHO and HCOOH. The chlorination of alcohol **4** in the presence of SOCl~2~ to produce **5** was successful \[[@B26-molecules-19-08803]\]. The *N*-mustard precursor **6** was synthesized by condensing compound **5** with diethanolamine in the presence of K~2~CO~3~/KI \[[@B27-molecules-19-08803]\]. The final target compound **7** was obtained from **6** by reacting with SOCl~2~ ([Scheme 1](#molecules-19-08803-f007_scheme1){ref-type="scheme"}).

![Synthesis of compounds **7a**--**b**.](molecules-19-08803-g007){#molecules-19-08803-f007_scheme1}

The synthesis of bis-naphthalimide derivatives is illustrated in [Scheme 2](#molecules-19-08803-f008_scheme2){ref-type="scheme"}. Starting from compound **2**, the target compounds **11a**,**b** were obtained following the procedures described below.

![Synthesis of bis-naphthalimide derivatives.](molecules-19-08803-g008){#molecules-19-08803-f008_scheme2}

2.2. Biological Assay
---------------------

### 2.2.1. Cytotoxic Activity

The *N*-mustard naphthalimide derivatives **7a**--**b**, **11a**--**b** and the precursors **6a**--**b**, **10a**--**b** in their dihydrochloride forms were screened for their cytotoxic activities against five cancer cell lines, which were HCT-116 (colorectal carcinoma), PC-3 (prostate carcinoma), U87 MG (brain tumor), Hep G2 (liver cancer), and SK-OV-3 (ovarian cancer), with an *in vitro* cell growth assay using amonafide as positive control. The results were listed in [Table 1](#molecules-19-08803-t001){ref-type="table"}. The activity of compound **11b** was the highest among all the compounds and was increased by several fold (1.4--11) compared to amonafide, while compound **7b** showed a similar activity with amonafide. *N*-mustards **7b** and **11b** displayed more activity than their precursors **6b**, **10b**. Furthermore, compared with compounds **7b** and **11b**, **7a** and **11a** unexpectedly showed much lower activities (\>10 μM). Because quaternary ammonium salts of **7a** and **11a** were used in this cytotoxicity assay, the six-membered rings in **7a** and **11a**, which make them less flexible, may be the reason for the lower activities.

molecules-19-08803-t001_Table 1

###### 

IC~50~ values of naphthalimide derivatives against five cancer cell lines ^a^.

  Compound ^b^    IC~5~ (μM)                                                     
  --------------- --------------- --------------- -------------- --------------- --------------
  **6a**          73.77 ± 2.54    225.80 ± 6.41   40.80 ± 3.14   42.81 ± 26.39   63.35 ± 5.42
  **6b**          6.96 ± 1.64     69.97 ± 10.14   10.24 ± 0.19   9.39 ± 4.37     12.76 ± 1.40
  **7a**          33.29 ± 3.13    73.10 ± 14.61   10.77 ± 0.07   15.38 ± 2.88    35.31 ± 5.69
  **7b**          2.42 ± 0.12     3.02 ± 0.34     1.95 ± 0.07    1.40 ± 0.07     3.59 ± 0.70
  **10a**         1.30 ± 0.09     2.98 ± 0.08     1.77 ± 0.14    1.25 ± 0.16     2.33 ± 0.28
  **10b**         2.80 ± 0.36     3.33 ± 0.17     2.04 ± 0.13    0.82 ± 0.06     2.43 ± 0.13
  **11a**         31.54 ± 18.66   96.35 ± 64.69   24.88 ± 3.17   31.76 ± 18.21   15.40 ± 6.22
  **11b**         1.01 ± 0.06     0.35 ± 0.03     0.39 ± 0.03    0.89 ± 0.15     0.61 ± 0.04
  **Amonafide**   4.81 ± 0.54     3.89 ± 0.28     2.60 ± 0.32    1.23 ± 0.07     5.10 ± 0.76

^a^ Cell growth inhibition was measured by the MTT assay, and values were expressed as mean IC~50~ of the triplicate experiment; ^b^ All these compounds (**6**, **7**, **10**, **11**) are in its di-hydrochloride forms.

We also screened all the synthetic intermediates in its mono-hydrochloride form against the same five cancer cell lines ([Table 2](#molecules-19-08803-t002){ref-type="table"}). It was unexpected to find that compounds **8a** and **8b** which acted only as DNA-intercalators, exhibited close activities to **11b**. These results indicated that *N*-mustards can increase the cytotoxic activity of the naphathalimide derivatives, but not efficiently.

molecules-19-08803-t002_Table 2

###### 

IC~50~ values of synthetic intermediates over five cancer cell lines ^a^.

  Compound ^b^    IC~5~ (μM)                                                    
  --------------- -------------- --------------- --------------- -------------- ---------------
  **3a**          13.45 ± 0.88   45.82 ± 3.13    15.39 ± 1.39    22.60 ± 8.29   24.18 ± 4.64
  **3b**          12.52 ± 1.47   49.17 ± 6.69    14.25 ± 1.19    12.17 ± 0.65   17.48 ± 1.68
  **4a**          12.00 ± 0.46   25.54 ± 2.24    14.08 ± 0.86    9.43 ± 2.39    15.07 ± 2.17
  **4b**          23.72 ± 2.53   67.16 ± 8.79    27.50 ± 5.02    18.80 ± 1.91   21.05 ± 3.09
  **5a**          8.44 ± 0.68    7.40 ± 0.64     3.33 ± 0.37     4.20 ± 0.20    16.71 ± 1.47
  **5b**          81.69 ± 3.79   64.16 ± 14.12   36.89 ± 13.15   31.19 ± 1.09   102.58 ± 6.99
  **8a**          0.78 ± 0.06    1.83 ± 0.07     0.77 ± 0.02     0.71 ± 0.10    0.89 ± 0.03
  **8b**          0.77 ± 0.05    1.38 ± 0.18     0.65 ± 0.02     0.56 ± 0.02    0.87 ± 0.03
  **9b**          2.07 ± 0.24    14.60 ± 0.53    2.26 ± 0.37     1.04 ± 0.07    5.29 ± 0.31
  **amonafide**   4.81 ± 0.54    3.89 ± 0.28     2.60 ± 0.32     1.23 ± 0.07    5.10 ± 0.76

^a^ Cell growth inhibition was measured by the MTT assay, and values were expressed as mean IC~50~ of the triplicate experiment. ^b^ All these compounds (**3**, **4**, **5**, **8**, **9**) are in its mono-hydrochloride forms.

![Fluorescence spectra of (**a**) **6b** (**b**) **7b** (**c**) **10b** (**d**) **11b**.](molecules-19-08803-g003){#molecules-19-08803-f003}

### 2.2.2. Fluorescence Studies

A fluorescence study was employed to evaluate the interaction properties of the synthesized derivatives with DNA. [Figure 3](#molecules-19-08803-f003){ref-type="fig"} illustrates the changes of fluorescence properties of compounds **6b**, **7b**, **10b** and **11b** before and after being mixed with calf thymus DNA (ctDNA).The solutions of various concentrations of compounds with ctDNA were incubated at 30 °C for 3 days, then the florescence spectra were recorded. We found that the fluorescence intensity of compound **6b** showed little change with or without ctDNA at all five concentrations, indicating a weak intercalating ability. On the contrary, compound **7b** exhibited an evident decrease of fluorescence intensity when ctDNA was added, which demonstrated the *N*-mustard is essential to increase the binding strength to DNA. Both compounds **10b** and **11b** showed obvious decreases of fluorescence intensity, but the difference between them is not significant. Those results indicate that: (1) an *N*-mustard residue is able to stabilize the DNA-compound complex after the intercalating process, and the binding potency is enhanced for *N*-mustard derivatives; (2) bis-naphthalimides **10b**, **11b** show generally much higher intercalating potential than mono-naphthalimides such as **6b**, **7b**, which is in accordance with previous research \[[@B19-molecules-19-08803]\].

![Agarose Gel Cross-Link Assay.](molecules-19-08803-g004){#molecules-19-08803-f004}

### 2.2.3. DNA Interstrand Cross-Linking Assay

To evaluate the potency of DNA interstrand cross-linking brought by the *N*-mustard moiety \[[@B15-molecules-19-08803]\], compounds **7a**, **b** and **11a**, **b** were selected to undergo an agarose gel cross-linking assay, at four concentration levels ([Figure 4](#molecules-19-08803-f004){ref-type="fig"}). Considering that naphthalimide chromophore can intercalate with DNA and so slow down DNA migration on the gel, **6a**,**b** and **10a**,**b** were employed, respectively, as controls for each mustine derivative. Compounds **7a**, **7b** and **11b** displayed DNA cross-linking potency at 1, 1 and 5 μM, respectively; while **11a** displayed almost no DNA cross-linking ability. The results for **7b**, **11a** and **11b** were consistent with their cytotoxic data. However, different from the cytotoxicity data, **7a** exhibited high DNA cross-linking activity, even at 1 μM concentration. The different performance of **7a** in cells and under agarose gel (with Tris-HCl buffer) conditions may result from its insufficient transmembrane access to the nucleus. The controls **10a** and **10b** displayed no DNA cross-linking abilities when compared with the *N*-mustards **11a** and **11b**, which showed similar activities in the previous tests. This result suggested the possibility that the *N*-mustard moiety did not show significant differences in *in vitro* tests, but played an efficient role in interacting with DNA.

### 2.2.4. Flow Cytometry Assay

Compounds that target DNA by intercalating or cross-linking often interfere with cellular DNA replication, thus inhibiting cell proliferation by inducing cell cycle arrest. To evaluate the effects of the compounds on cell cycle progression, the cell cycle distribution of HCT-116 cells was examined by flow cytometry after treatment with indicated concentrations of compounds **7b**, **9b** and **11b** for 24 h. As shown in [Figure 5](#molecules-19-08803-f005){ref-type="fig"}, compounds **7b** and **11b** induced G2/M and S phase cell cycle arrest, suggesting that these compounds could interfere with DNA synthesis. Compound **11b** showed a more pronounced arrest in G2/M phase at 1 μM than **7b**, which is in agreement with the higher cytotoxicity associated with **11b**. However, compound **9b**, a homo-*N*-mustard, exhibited marginal effects on the cell cycle distribution, even at 5 μM, implying the *N*-mustard moiety is essential for inhibition of DNA synthesis.

![Effects of compounds on cell cycle distribution of HCT-116 cells.](molecules-19-08803-g005){#molecules-19-08803-f005}

### 2.2.5. Immunoblotting Assay

Poly(ADP-ribose) polymerase (PARP-1) is specifically cleaved by caspases during the execution phase of apoptosis in response to DNA damage, thus its cleavage has been regarded as a biomarker of apoptosis \[[@B28-molecules-19-08803]\]. Therefore, the cleavage of PARP-1 in HCT-116 cells treated with various compounds was detected by western blotting. As shown in [Figure 6](#molecules-19-08803-f006){ref-type="fig"}, both **7b** and **11b** induced significant cleavage of the original 116 kDa PARP-1 into 89 kDa and 24 kDa fragments, suggesting that these two compounds induced DNA-damage related apoptosis. In agreement with the results above, the homo-mustard **9b** showed no observable effect on the cleavage of PARP-1. Taken together, the above results suggest that compounds **7b** and **11b** induced DNA damage-related cell cycle arrest and apoptosis in HCT-116 cells, but **9b** might have a different mechanism of action.

![Effect of compounds on PARP-1 cleavage in HCT-116 cell.](molecules-19-08803-g006){#molecules-19-08803-f006}

3. Experimental Section
=======================

3.1. General Information
------------------------

All the solvents were of analytical grade. ^1^H-NMR and ^13^C-NMR spectra were obtained with JEOL-300 all examples below are 300 MHz but in [Supplementary file](#app1-molecules-19-08803){ref-type="app"} spectra are labelled as 400 Mhz. Explain this confusing situation spectrometers. The chemical shifts were reported in ppm using TMS as internal standard. High resolution mass spectrometry was measured on a Bruker MicrOTOF-Q. Column chromatography was conducted on silica gel (200\~300 mesh). Temperature range for rt is 25 ± 2 °C.

3.2. Synthesis
--------------

*2-(3-Hydroxypropyl)-1H-benzo\[de\]isoquinoline-1,3(2H)-dione* (**1**) \[[@B24-molecules-19-08803]\]. A mixture of 1,8-naphthalic anhydride (4 g, 20.8 mmol) and 3-amino-1-propanol (1.86 mL, 24.6 mmol) in ethanol (40 mL) was heated under reflux for 5 h. The resulting mixture was concentrated by evaporating ethanol under reduced pressure to afford a solid residue, which was purified by column chromatography over silica gel (CH~2~Cl~2~/MeOH = 1:1) to afford compound **1** as an off-white solid (4.27 g, 83%).

*2-(3-Bromopropyl)-1H-benzo\[de\]isoquinoline-1,3(2H)-dione* (**2**) \[[@B25-molecules-19-08803]\]. To a solution of compound **1** (2 g, 7.84 mmol) and NBS (2.12 g, 11.9 mmol) in dichloromethane (20 mL, dry) was added PPh~3~ (2.49 g, 8.2 mmol) in portions in an ice bath. The resulting solution was kept at room temperature overnight, and then purified by column chromatography over silica gel (petroleum ether/CH~2~Cl~2~ = 3:1) to afford compound **2** (2.25 g, 90%).

*N-\[2-(1,3-Dioxo-2,3-dihydro-1H-benz\[de\]-isoquinolin-2-yl)propyl\]-ethanolamine* (**3a**). A mixture of compound **2** (1 g, 3.15 mmol), ethanolamine (2 mL, 33.1 mmol) and K~2~CO~3~ (1.8 g, 13.0 mmol) in 10 mL of CH~3~CN was heated at 70 °C for 30 h. The resulting mixture was filtered to remove the K~2~CO~3~ residue, condensed *in vacuo*, then dissolved in H~2~O (80 mL) and extracted with CH~2~Cl~2~ (100 mL). The extract was dried over Na~2~SO~4~ and purified by column chromatography (CH~2~Cl~2~/MeOH = 20:1\~10:1) to yield pure **3a** (0.79 g, 80%) as a faint yellow solid. ^1^H-NMR (300 MHz, CDCl~3~) δ~H~ (ppm): 1.94--2.01 (m, 2H), 2.69--2.76 (m, 4H, NHCH~2~ and OH), 2.82 (t, 2H, *J* = 5.1 Hz), 3.66 (t, 2H, *J* = 5.1 Hz), 4.29 (t, 2H, *J* = 6.9 Hz), 7.75 (dd, 2H, *J* = 7.5, 8.1 Hz), 8.21 (d, 2H, *J* = 8.4 Hz), 8.59 (d, 2H, *J* = 7.2 Hz). ^13^C-NMR (75 MHz, CDCl~3~): δ 164.3(2C), 134.0 (2C), 131.3 (4C), 126.9 (2C), 122.5 (2C), 60.6, 50.9, 46.2, 38.1, 28.3.HRMS (ESI): Calcd for C~17~H~19~N~2~O~3~: 299.1390 \[M+H\]^+^, Found: 299.1383 \[M+H\]^+^.

*N-\[2-(1,3-Dioxo-2,3-dihydro-1H-benz\[de\]-isoquinolin-2-yl)propyl\]-3-amino-1-propanol* (**3b**). Compound **3b** was synthesized by a similar procedure as the synthesis of **3a**. Compound **2** (1 g, 3.15 mmol) and 3-amino-1-propanol (2 mL, 27.1 mmol) were employed to produce **3b** (yellow oil, 0.89 g, 91%). ^1^H-NMR (300 MHz, CDCl~3~) δ~H~ (ppm): 1.73--1.76 (m, 2H), 1.95--2.00 (m, 2H), 2.73 (t, 2H, *J* = 6.6 Hz), 2.90 (t, 1H, *J* = 5.4 Hz, NH), 3.46--3.47 (m, 3H, CH~2~N, OH), 3.83 (t, 2H, *J* = 5.1 Hz), 4.24 (t, 2H, *J* = 6.3 Hz), 7.71--7.76 (m, 2H), 8.19 (d, 2H, *J* = 7.2 Hz), 8.70 (d, 2H, *J* = 6.0 Hz). ^13^C-NMR (75 MHz, CDCl~3~): δ 164.2 (2C), 133.9 (2C), 131.4, 131.2 (3C), 126.8 (2C), 122.3 (2C), 63.7, 49.2, 46.7, 37.9, 30.6, 27.9; HRMS (ESI): Calcd for C~18~H~21~N~2~O~3~: 313.1547 \[M+H\]^+^, Found: 313.1555 \[M+H\]^+^.

*N-\[2-(1,3-Dioxo-2,3-dihydro-1H-benz\[de\]-isoquinolin-2-yl)propyl\]-N-methylethanolamine* (**4a**). To formaldehyde (37%, 1.2 mL) was added formic acid (5 mL) dropwise in an ice bath, and the resulting solution was added into compound **3a** (711 mg, 2.39 mmol) and stirred for 10 min in an ice bath, then heated to 105 °C overnight. Removal of residual formaldehyde and formic acid under reduced pressure gave crude product, which was dissolved in water and treated with Na~2~CO~3~ to pH \> 7, and extracted with CH~2~Cl~2~. The organic layer was dried with Na~2~SO~4~ and purified by column chromatography (CHCl~3~/MeOH = 30:1) to yield compound **4a** (yellow oil, 0.64 g, 85.6%). ^1^H-NMR (300 MHz, CDCl~3~) δ~H~ (ppm): 1.90--1.99 (m, 2H), 2.29 (s, 3H), 2.54--2.59 (m, 4H), 3.02 (s, 1H), 3.61 (t, 2H, *J* = 5.1 Hz), 7.75 (dd, 2H, *J* = 7.5, 8.1 Hz), 8.21 (d, 2H, *J* = 8.4 Hz), 8.59--8.61 (m, 2H). ^13^C-NMR (75 MHz, CDCl~3~): δ 164.2 (2C), 133.9 (2C), 131.5, 131.2 (3C), 126.9 (2C), 122.6 (2C), 59.0, 58.5, 55.2, 41.4, 38.5, 25.7; HRMS (ESI): Calcd for C~18~H~21~N~2~O~3~: 313.1547 \[M+H\]^+^, Found: 313.1560 \[M+H\]^+^.

*N-\[2-(1,3-Dioxo-2,3-dihydro-1H-benz\[de\]-isoquinolin-2-yl)propyl\]-N-methyl-3-amino-1-propanol* (**4b**). Compound **4b** was synthesized by a similar procedure as the synthesis of **4a**. Compound **3b** (852 mg, 2.72 mmol) was employed to produce **4b** (yellow oil, 0.68 g, 77%). ^1^H-NMR (300 MHz, CDCl~3~) δ~H~ (ppm): 1.70--1.77 (m, 2H), 1.90--2.00 (m, 2H), 2.31 (s, 3H), 2.55 (t, 2H, *J* = 7.5 Hz), 2.64 (t, 2H, *J* = 5.7 Hz), 3.84 (t, 2H, *J* = 5.4 Hz), 4.22 (t, 2H, *J* = 7.5 Hz), 5.30 (s, 1H, OH), 7.75 (dd, 2H, *J* = 8.4, 7.2 Hz), 8.21 (d, 2H, *J* = 8.4 Hz), 8.59 (d, 2H, *J* = 7.2 Hz). ^13^C-NMR (75 MHz, CDCl~3~): δ 164.1 (2C), 133.9 (2C), 131.5, 131.2 (3C), 126.9 (2C), 122.5 (2C), 64.3, 57.8, 55.9, 41.8, 38.5, 27.8, 25.6; HRMS (ESI): Calcd for C~19~H~23~N~2~O~3~: 327.1703 \[M+H\]^+^, Found: 327.1704 \[M+H\]^+^.

*N-\[2-(1,3-Dioxo-2,3-dihydro-1H-benz\[de\]-isoquinolin-2-yl)propyl\]-N-methyl-2-chloroethanamine* (**5a**). To a solution of compound **4a** (579 mg, 1.86 mmol) in CHCl~3~ (30 mL) was added SOCl~2~ (1 mL) dropwise and the mixture was stirred at room temperature for 48 h. Removal of the solvent under reduced pressure gave the crude product, which was dissolved in water, treated with Na~2~CO~3~ until pH \> 7, and extracted with CH~2~Cl~2~. The organic layer was dried with Na~2~SO~4~ and purified by column chromatography (CHCl~3~/MeOH = 50:1) to yield compound **5a** (pale yellow solid, 80.0%). ^1^H-NMR (300 MHz, CDCl~3~) δ~H~ (ppm): 1.87--1.97 (m, 2H), 2.32 (s, 3H), 2.59 (t, 2H, *J* = 7.2 Hz), 2.74 (t, 2H, *J* = 7.2 Hz), 3.56 (t, 2H, *J* = 7.2 Hz), 4.23 (t, 2H, *J* = 7.5 Hz), 7.75 (dd, 2H, *J* = 7.8, 7.5 Hz), 8.21 (d, 2H, *J* = 8.1 Hz), 8.59 (d, 2H, *J* = 7.2 Hz). ^13^C-NMR (75 MHz, CDCl~3~): δ 164.2 (2C), 133.9 (2C), 131.6, 131.2, 131.1 (2C), 126.9 (2C), 122.7 (2C), 58.9, 55.3, 42.1, 41.6, 38.7, 25.7; HRMS (ESI): Calcd for C~18~H~20~ClN~2~O~2~: 331.1208 \[M+H\]^+^, Found: 331.1219 \[M+H\]^+^.

*N-\[2-(1,3-Dioxo-2,3-dihydro-1H-benz\[de\]-isoquinolin-2-yl)propyl\]-N-methyl-3-chloro-1-propylamine* (**5b**). Compound **5b** was synthesized by a similar procedure as the synthesis of **5a**. Compound **4b** (625 mg, 1.92 mmol) was employed to produce **5b** (light yellow solid, 0.55 g, 82.9%). ^1^H-NMR (300 MHz, CDCl~3~) δ~H~ (ppm): 2.36--2.39 (brs, 4H), 3.78 (s, 3H), 3.16 (brs, 4H), 3.67 (t, 2H, *J* = 5.4 Hz), 4.32 (t, 2H, *J* = 6.9 Hz), 7.78 (t, 2H, *J* = 7.8 Hz), 8.25 (d, 2H, *J* = 8.4 Hz), 8.60 (d, 2H, *J* = 7.2 Hz). ^13^C-NMR (75 MHz, CDCl~3~): δ 164.2 (2C), 134.4 (2C), 131.6 (4C), 128.1, 127.0, 122.1 (2C), 54.3, 54.1, 41.8, 40.1, 37.6, 26.9, 22.9; HRMS (ESI): Calcd for C~19~H~22~ClN~2~O~2~: 345.1364 \[M+H\]^+^, Found: 345.1361 \[M+H\]^+^.

*N-\[2-(1,3-Dioxo-2,3-dihydro-1H-benz\[de\]-isoquinolin-2-yl)propyl\]-N-methyl-N\',N\'-bis(2-hydroxyethyl)-ethylenediamine* (**6a**). A mixture of compound **5a** (431 mg, 1.31 mmol), K~2~CO~3~ (300 mg, 2.17 mmol), KI (100 mg, 0.60 mmol) and diethanolamine (0.8 mL) in CH~3~CN (15 mL) was stirred at 80 °C under N~2~ for 72 h. The resulting mixture was evaporated under reduced pressure to give the crude product. The residue was dissolved in water (50 mL) and extracted with CH~2~Cl~2~. The organic layer was dried with Na~2~SO~4~ and purified by column chromatography (CHCl~3~/MeOH = 30:1\~10:1) to yield compound **6a** (yellow oil, 58%). ^1^H-NMR (300 MHz, CDCl~3~) δ~H~ (ppm): 1.93--1.98 (m, 2H), 2.28 (s, 3H), 2.49--2.71 (m, 10H), 3.58 (m, 4H), 4.20 (t, 2H, *J* = 7.5 Hz), 4.34 (brs, 2H, OH), 7.70--7.75 (m, 2H), 8.18 (d, 2H, *J* = 8.1 Hz), 8.56 (d, 2H, *J* = 7.2 Hz). ^13^C-NMR (75 MHz, CDCl~3~): δ 164.0 (2C), 133.8 (2C), 131.4, 131.1 (3C), 126.8 (2C), 122.4 (2C), 59.9 (2C), 57.3 (2C), 56.1, 55.1, 51.7, 41.5, 38.6, 25.0; HRMS (ESI): Calcd for C~22~H~30~N~3~O~4~: 400.2231 \[M+H\]^+^, Found: 400.2241 \[M+H\]^+^.

*N-\[2-(1,3-Dioxo-2,3-dihydro-1H-benz\[de\]-isoquinolin-2-yl)propyl\]-N-methyl-N\',N\'-bis(2-hydroxyethyl)-1,3-diamine* (**6b**). Compound **6b** was synthesized by a similar procedure as the synthesis of **6a**. Compound **5b** (451 mg, 1.31 mmol) was employed to produce **6b** (yellow oil, 91.2%). ^1^H-NMR (300 MHz, CDCl~3~) δ~H~ (ppm): 1.66 (t, 2H, *J* = 6.3 Hz), 1.95 (t, 2H, *J* = 6.9 Hz), 2.25 (s, 3H), 2.47--2.65 (m, 10H), 3.63 (t, 3H, *J* = 5.1 Hz), 3.99 (brs, 2H), 4.21 (t, 2H, *J* = 7.5 Hz), 7.74 (t, 2H, *J* = 7.5 Hz), 8.20 (d, 2H, *J* = 8.1 Hz), 8.58 (d, 2H, *J* = 7.5 Hz). ^13^C-NMR (75 MHz, CDCl~3~): δ 164.1 (2C), 133.9 (2C), 131.4, 131.1 (2C), 128.0, 126.9 (2C), 122.5 (2C), 59.9 (2C), 56.1 (2C), 54.9, 54.6, 52.0, 41.9, 38.8, 25.0, 24.4; HRMS (ESI): Calcd for C~23~H~32~N~3~O~4~: 414.2387 \[M+H\]^+^, Found: 414.2384 \[M+H\]^+^.

*N-\[2-(1,3-Dioxo-2,3-dihydro-1H-benz\[de\]-isoquinolin-2-yl)propyl\]-N-methyl-N\',N\'-bis(2-chloroethyl)-ethylenediamine* (**7a**). The solution of compound **6a** (75 mg, 0.19 mmol) in SOCl~2~ (2 mL) was stirred at room temperature overnight. The remaining SOCl~2~was completely removed by adding Et~2~O and then condensing the mixture several times *in vacuo*. The residue was dissolved in CH~2~Cl~2~; by adding Et~2~O into the solution, a white solid was formed and a gray solid was obtained by filtration with a yield of 85%. The purity of **7a** as determined by NMR meets the requirements for the cytotoxicity assay. ^1^H- NMR (300 MHz, D~2~O) δ~H~ (ppm): 1.93 (brs, 2H), 2.88 (s, 3H), 3.46--3.86 (m, 14H), 7.24--7.30 (m, 2H), 7.72--7.78 (m, 4H). ^13^C-NMR (75 MHz, D~2~O): δ165.2 (2C), 135.8 (2C), 131.9, 130.9 (3C), 127.5 (2C), 120.3 (2C), 55.6(4C), 51.5, 48.4, 40.7, 39.1, 37.6, 24.9.HRMS (ESI): Calcd for C~22~H~28~Cl~2~N~3~O~2~: 436.1553 \[M+H\]^+^, Found: 436.1559 \[M+H\]^+^.

*N-\[2-(1,3-Dioxo-2,3-dihydro-1H-benz\[de\]-isoquinolin-2-yl)propyl\]-N-methyl-N\',N\'-bis(2-chloroethyl)-1,3-diamine* (**7b**). To a solution of compound **6b** (123 mg, 0.30 mmol) in CHCl~3~ (20 mL) was added SOCl~2~ (0.15 mL) dropwise, and the solution became turbid. After the reaction was kept at 65 °C for 4 h, the solution became clear. The solvent was removed *in vacuo* to give the crude product, which was dissolved in conc. NaHCO~3~ solution and extracted with CH~2~Cl~2~. The organic layer was washed by conc. NaCl, dried by Na~2~SO~4~ and purified by column chromatography (CHCl~3~/MeOH = 50:1) to yield 7b (yellow oil, 45%) ^1^H-NMR (300 MHz, CDCl~3~) δ~H~(ppm): 1.62 (t, 2H, *J* = 7.2 Hz), 1.92--1.99 (m, 2H), 2.27 (s, 3H), 2.43 (t, 2H, *J* = 6.6 Hz), 2.52--2.62 (m, 4H), 2.84 (t, 4H, *J* = 7.2 Hz), 3.50 (t, 4H, *J* = 6.9 Hz), 4.22 (t, 2H, *J* = 7.5 Hz), 7.74 (t, 2H, *J* = 7.8 Hz), 8.19 (d, 2H, *J* = 7.8 Hz), 8.57 (d, 2H, *J* = 7.2 Hz). ^13^C-NMR (75 MHz, CDCl~3~): δ 164.0 (2C), 133.8 (2C), 131.4, 131.1 (3C), 127.9, 126.8, 122.5 (2C), 56.3 (2C), 55.2, 54.9, 52.4, 41.9 (2C), 41.7, 38.7, 25.4, 25.2; HRMS (ESI): Calcd for C~23~H~30~Cl~2~N~3~O~2~: 450.1710 \[M+H\]^+^, Found:450.1716 \[M+H\]^+^.

*N,N-Bis\[2-(1,3-dioxo-2,3-dihydro-1H-benz\[de\]-isoquinolin-2-yl)propyl\]ethanolamine* (**8a**). A mixture of compound **2** (318 mg, 1 mmol), ethanolamine (30 μL, 0.5 mmol) and K~2~CO~3~ (552 mg, 4 mmol) in CH~3~CN (10 mL) was heated at 80 °C in and oil bath under N~2~ for 24 h. The resulting mixture was filtrated to remove the solid salt and concentrated *in vacuo*, then purified by column chromatography over silica gel (CH~2~Cl~2~/MeOH = 30:1\~20:1) to yield **8a** (light yellow solid, 174 mg, 65%). ^1^H-NMR (300 MHz, CDCl~3~) δ~H~(ppm): 1.87--1.96 (m, 4H), 2.64--2.69 (m, 6H), 3.63 (m, 2H), 4.24 (t, 4H, *J* = 7.5 Hz), 7.71 (t, 4H, *J* = 7.5 Hz), 8.16 (d, 4H, *J* = 8.1 Hz), 8.54 (d, 4H, *J* = 7.2 Hz). ^13^C-NMR (75 MHz, CDCl~3~): δ 164.0 (4C), 133.8 (4C), 131.4 (2C), 131.1 (4C), 128.0 (2C), 126.8 (4C), 122.6 (4C), 59.1, 56.3, 51.6 (2C), 38.6 (2C), 25.7 (2C); HRMS (ESI): Calcd for C~32~H~30~N~3~O~5~: 536.2180 \[M+H\]^+^, Found:536.2184 \[M+H\]^+^.

*N,N-Bis\[2-(1,3-dioxo-2,3-dihydro-1H-benz\[de\]-isoquinolin-2-yl)propyl\]-3-amino-1-propanol* (**8b**). Compound **8b** was synthesized by a similar procedure as the synthesis of **8a**. Compound **2** (318 mg, 1 mmol), 3-amino-1-propanol (0.037 mL, 0.5 mmol) and K~2~CO~3~ (552 mg, 4 mmol) were employed to produce **8b** (light yellow oil, 137 mg, 50%). ^1^H-NMR (300 MHz, CDCl~3~) δ~H~(ppm): 1.76 (m, 2H), 1.95 (m, 4H), 2.64--2.72 (m, 6H), 3.88 (t, 2H), 4.21 (t, 4H, *J* = 7.5 Hz), 7.69 (t, 4H, *J* = 7.2 Hz), 8.15 (d, 4H, *J* = 8.4 Hz), 8.49 (d, 4H, *J* = 7.5 Hz). ^13^C-NMR (75 MHz, CDCl~3~):δ 163.9 (4C), 133.7 (4C), 131.3 (2C), 130.9 (4C), 127.8 (2C), 126.7 (4C), 122.3 (4C), 62.9, 52.7, 51.6 (2C), 38.7 (2C), 28.4, 25.2 (2C); HRMS (ESI): Calcd for C~33~H~32~N~3~O~5~: 550.2336 \[M+H\]^+^, Found: 550.2346 \[M+H\]^+^.

*N,N-Bis\[2-(1,3-dioxo-2,3-dihydro-1H-benz\[de\]-isoquinolin-2-yl)propyl\]-3-chloro-1-propylamine* (**9b**). To a solution of compound **8b** (1.100 g, 2.0 mmol) in CHCl~3~ (20 mL) was added SOCl~2~ (0.8 mL) dropwise and the mixture was stirred at room temperature for 2 days. The resulting mixture was concentrated under reduced pressure to give a yellow solid residue. The residue was rapidly purified by column chromatography over silica gel (CH~2~Cl~2~/MeOH = 40:1) to yield **9b** (light yellow solid, 87.5%). Compound **9b** was easily transferred into the corresponding ammonium salt, so it should be used immediately for next step. ^1^H-NMR (300 MHz, CDCl~3~) δ~H~ (ppm): 1.88--2.04 (m, 6H), 2.64 (t, 6H, *J* = 6.3 Hz), 3.69 (t, 2H, *J* = 6.3 Hz), 4.21 (t, 4H, *J* = 6.6 Hz), 7.68 (t, 4H, *J* = 7.2 Hz), 8.26 (d, 4H, *J* = 8.1 Hz), 8.77 (d, 4H, *J* = 7.2 Hz). ^13^C-NMR (75 MHz CDCl~3~): δ 163.8 (4C), 133.6 (4C), 131.3 (2C), 130.9 (4C), 127.8 (2C), 126.7 (4C), 122.5 (4C), 51.6, 50.7 (2C), 43.4, 38.8 (2C), 30.5, 25.5 (2C); HRMS (ESI): Calcd for C~33~H~30~ClN~3~O~4~: 568.2003 \[M+H\]^+^, Found: 568.1982 \[M+H\]^+^.

*N,N-Bis\[2-(1,3-dioxo-2,3-dihydro-1H-benz\[de\]-isoquinolin-2-yl)propyl\]-N\',N\'-bis(2-hydroxyethyl)-ethylenediamine* (**10a**). The synthesis of compound **10a** was divided into two parts. Firstly, compound **8a** (560 mg, 1.05 mmol) was employed to produce **9a** through a similar procedure as **9b**. Then compound **9a** was directly used for the next step. A mixture of **9a** (350 mg, 0.63 mmol), K~2~CO~3~ (540 mg, 3.91 mmol), KI (100 mg, 0.60 mmol) and diethanolamine (0.8 mL) in CH~3~CN (10 mL) was refluxed under N~2~ for 60 h. The resulting mixture was filtrated to remove solid K~2~CO~3~, and then concentrated under reduced pressure. The crude product was purified by column chromatography over silica gel (CHCl~3~/MeOH = 30:1) to yield 10a (light yellow oil, 86.0%).^1^H-NMR (300 MHz, CDCl~3~) δ~H~ (ppm): 1.94 (t, 4H, *J* = 6.9 Hz), 2.62--2.70 (m, 12H), 3.61 (brs, 6H), 4.22 (t, 4H, *J* = 6.6 Hz), 7.72 (t, 4H, *J* = 7.2 Hz), 8.18 (d, 4H, *J* = 8.1 Hz), 8.54 (d, 4H, *J* = 7.2 Hz). ^13^C-NMR (75 MHz, CDCl~3~): δ 164.1 (4C), 133.8 (4C), 131.4 (2C), 131.1 (6C), 126.8 (4C), 122.6 (4C), 59.9 (2C), 57.2 (2C), 52.6, 52.4, 51.4 (2C), 38.9 (2C), 24.8 (2C); HRMS (ESI): Calcd for C~36~H~39~N~4~O~6~: 536.2180 \[M+H\]^+^, Found:536.2848 \[M+H\]^+^.

*N,N-Bis\[2-(1,3-dioxo-2,3-dihydro-1H-benz\[de\]-isoquinolin-2-yl)propyl\]-N\',N\'-bis(2-hydroxyethyl)-1,3-diamine* (**10b**). Compound **10b** was synthesized by a similar procedure as the synthesis of **10a**. Compound **8b** (1.000 g, 1.8 mmol) was employed to produce **9b**, which was then used immediately for the next step to yield **10b** (light yellow oil, 81.6%). ^1^H-NMR (300 MHz, CDCl~3~) δ~H~ (ppm): 1.68--1.73 (t, 2H), 1.89--1.96 (m, 4H), 2.56--2.68 (m, 12H), 3.38 (brs, 2H), 3.64--3.67 (t, 4H), 4.22 (t, 4H, *J* = 7.5 Hz), 7.72 (t, 4H, *J* = 7.5 Hz), 8.17 (d, 4H, *J* = 7.8 Hz), 8.55 (d, 4H, *J* = 7.5 Hz). ^13^C-NMR (75 MHz, CDCl~3~): δ164.2 (4C), 133.8 (4C), 131.5 (2C), 131.2 (4C), 128.0 (2C), 126.9 (4C), 122.6 (4C), 59.8 (2C), 56.6 (2C), 52.8, 51.8 (2C), 51.1, 39.0 (2C), 25.3 (2C), 24.8; HRMS (ESI): Calcd for C~37~H~41~N~4~O~6~: 637.3021 \[M+H\]^+^, Found: 637.3027 \[M+H\]^+^.

*N,N-Bis\[2-(1,3-dioxo-2,3-dihydro-1H-benz\[de\]-isoquinolin-2-yl)propyl\]-N\',N\'-bis(2-chloroethyl)--ethylenediamine hydrochloride* (**11a**). The solution of compound **10a** (50 mg, 0.08 mmol) in SOCl~2~ (1 mL) was stirred at room temperature overnight. The remaining SOCl~2~ was completely removed by adding Et~2~O and then condensed for several times *in vacuo*. The residue was dissolved in a mixed solution of methanol and a little methylene chloride, then a drop of concentrated hydrochloric acid was added to afford a white solid precipitate. The suspension was filtered to yield crude product **11a** hydrochloride as white solid (30 mg, 51.0%). ^1^H-NMR (300 MHz, DMSO-*d*~6~) δ~H~(ppm): 2.09 (brs, 4H), 3.07--3.77 (brs, 16H), 4.09 (t, 4H, *J* = 6.3 Hz), 7.82 (t, 4H, *J* = 7.8 Hz), 8.36--8.44 (m, 8H). ^13^C- NMR (75 MHz, DMSO-*d*~6~): δ 163.7 (4C), 134.5 (4C), 131.3 (2C), 130.8 (4C), 127.4 (2C), 127.2 (4C), 122.1 (4C), 54.4 (2C), 50.3 (2C), 47.6 (2C), 37.2 (4C), 22.1 (2C); HRMS (ESI): Calcd for C~36~H~37~Cl~2~N~4~O~4~: 659.2186 \[M+H\]^+^, Found:659.2180 \[M+H\]^+^.

*N,N-Bis\[2-(1,3-dioxo-2,3-dihydro-1H-benz\[de\]-isoquinolin-2-yl)propyl\]-N\',N\'-bis(2-chloroethyl)-1,3-diamine* (**11b**). To a solution of compound **10b** (190 mg, 0.30 mmol) in CHCl~3~ (25 mL) was added SOCl~2~ (0.15 mL) dropwise and the mixture stirred at 65 °C for 2 h. The solvent was removed under reduced pressure, then water (20 mL) and solid Na~2~CO~3~ were added to neutralize the solution, which was extracted with CH~2~Cl~2~ (50 mL). The organic layer was washed with saturated NaCl, dried over MgSO~4~, concentrated and then purified by column chromatography over silica gel (CHCl~3~/MeOH = 50:1) to yield **11b** (yellow oil, 77.0%). ^1^H-NMR (300 MHz, CDCl~3~) δ~H~ (ppm): 1.65 (brs, 2H), 1.92 (brs, 4H), 2.63--2.67 (m, 8H), 2.86 (t, 4H, *J* = 7.2 Hz), 3.51 (t, 4H, *J* = 7.2 Hz), 4.23 (t, 4H, *J* = 7.2 Hz), 7.72 (t, 4H, *J* = 7.8 Hz), 8.18 (d, 4H, *J* = 7.8 Hz), 8.54 (d, 4H, *J* = 7.2 Hz). ^13^C-NMR (75 MHz, CDCl~3~): δ 164.0 (4C), 133.7 (4C), 131.5 (2C), 131.1 (4C), 128.0 (2C), 126.8 (4C), 122.6 (4C), 56.4 (2C), 52.7, 51.6 (2C), 51.3, 42.0 (2C), 38.8 (2C), 25.2 (3C); HRMS (ESI): Calcd for C~37~H~39~Cl~2~N~4~O~4~: 673.2343 \[M+H\]^+^, Found: 673.2341 \[M+H\]^+^.

3.3. Fluorescence Study Experiment
----------------------------------

Each compound was divided into two groups: one was added with a constant concentration of ctDNA (calf thymus DNA, 50 μM) and the other was without the ctDNA as control. Various concentrations of compounds ranging from 1 μM to 25 μM (1, 5, 10, 20 and 25 μM) were used. To every sample was added Tris-HCl buffer (25 mM, pH = 7.4) to get a final volume of 4 mL, which was stirred constantly at 30 °C in the dark for 3 days before recording each spectrum.

3.4. Agarosegel Cross-Linking Assay
-----------------------------------

Each compound was tested at four concentrations (1, 5, 10, 50 μM). To each sample was added 2 μL plasmid DNA (PUC-19, 0.16 μg/μL) and various concentrations of compounds, diluted by Tris-HCl buffer (0.05 M, pH = 7.4) to reach a final volume of 15 μL. Every group has a pure DNA sample as blank control and its own control sample by using its own precursor in concentration of 10 μM. All the above samples were incubated at 37 °C for 1 h and separated on an agarose gel (120 V, 45 min).

3.5. In Vitro Cytotoxicity Evaluation
-------------------------------------

All the compounds were tested in their mono- or dihydrochloride form. The samples were prepared by adding a stoichiometric amount of 1 M HCl to the solution, and then removing the solvent to obtain the target compounds. All cells used in the research were prepared at 3.5 × 10^4^ cells/mL concentration and each 100 μL cells suspension was seeded in 96-well cell incubated for 24 h (37 °C, 5% CO~2~). Then each solution was added and incubated for another 72 h. For the control group, equivalent concentration of DMSO (final concentration 0.5%) was added. MTT (3-\[4,5-dimethylthiazol-2yl\]-diphenyltetrazolium bromide) method was employed to measure the number of surviving cells and the OD value was recorded at 492 nm/620 nm. The IC~50~ values were calculated using Prism Graphpad software of the triplicate experiment.

3.6. Flow Cytometry Assay
-------------------------

Cells were trypsinized and washed twice with PBS, then fixed in 75% alcohol for at least 30 min at 4 °C. The fixed cells were recovered by centrifugation and washed twice with PBS, and then stained with PI in PBS containing RNAase and 0.1% Triton-X100 for 30 min at 37 °C. The cellular DNA content was measured by a FACScalibur flow cytometer (BD Bioscience, San Jose, CA, USA).

3.7. Immunoblotting Assay
-------------------------

Cells were lysed using RIPA lysis buffer containing PMSF and phosphatase/protease inhibitors. The total cellular protein extracts was qualified by BCA assay. 20 μg of total protein was resolved on 10% SDS-PAGE, then electro-transferred onto PVDF membranes, and incubated with appropriate antibodies overnight at 4 °C, then washed in PBS containing 0.1% Tween 20 and incubated with corresponding secondary antibodies for 1 h at room temperature. After that the membranes were developed with the enhanced chemiluminescence Western Blotting detection reagent (Amersham-Pharmacia, Piscataway, NJ, USA).

4. Conclusions
==============

A series of mono- and bisnaphthalimide *N*-mustard derivatives were synthesized as potent antitumor agents. Through conjugating *N*-mustard to naphthalimide, improved cytotoxicity was obtained. Compound **11b** exhibited considerably cytotoxicity compared with amonafide, and showed potency as an antitumor agent. Even though more investigation is still needed to evaluate the efficiency of the *N*-mustard moiety, the bioactivity results suggest that the length of the flexible amine link and naphthalimide core could improve the cytotoxicity. Our work is meaningful in compensating for the lack of research in this field of combining *N*-mustards with naphthalimides.
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